Moderna (MRNA) Stock Climbs 16% on Melanoma Vaccine Breakthrough - Blockonomi

Moderna shares surged 16% to $50 on Wednesday following positive five-year melanoma vaccine trial data • Combined treatment with Merck’s Keytruda showed 49% reduction in cancer recurrence or death ris... [3111 symbols]

Últimos artigos